UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

Annals of oncology, 2013-02, Vol.24 (2), p.343-349

2013

Volltextzugriff (PDF)

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

Annals of oncology, 2017-08, Vol.28 (8), p.1988-1995

2017

Volltextzugriff (PDF)

HSP90 as a marker of progression in melanoma

Annals of oncology, 2008-03, Vol.19 (3), p.590-594

2008

Volltextzugriff (PDF)

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer

Annals of oncology, 2010-03, Vol.21 (3), p.466-473

2010

Volltextzugriff (PDF)

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

Journal of Cancer, 2014-01, Vol.5 (3), p.166-172

2014

Volltextzugriff (PDF)

Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1077-1082

2014

Volltextzugriff (PDF)

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma

Oncogene, 2014-08, Vol.33 (34), p.4330

2014

Volltextzugriff (PDF)

Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer

Oncogene, 2009-03, Vol.28 (9), p.1176-1186

2009

Volltextzugriff (PDF)

Identification of Two Forms of Human Plasma Renalase, and Their Association With All-Cause Mortality

Kidney international reports, 2020-03, Vol.5 (3), p.362-368

2020

Volltextzugriff (PDF)

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten–/– melanoma

Oncogene, 2014-08, Vol.33 (34), p.4330-4339

2014

Volltextzugriff (PDF)

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S720-S721

2015

Volltextzugriff (PDF)

Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival

Cancer research (Chicago, Ill.), 2003-12, Vol.63 (23), p.8103-8107

2003

Volltextzugriff (PDF)

Histopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma

Journal of cutaneous pathology, 2020-03, Vol.47 (3), p.226-240

2020

Volltextzugriff (PDF)

1582P Real-world management of immune-related adverse events in the community setting

Annals of oncology, 2022-09, Vol.33, p.S1268-S1269

2022

Volltextzugriff (PDF)

LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma

Journal of investigative dermatology, 2019-09, Vol.139 (9), p.B19-B19

2019

Volltextzugriff (PDF)

1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study

Annals of oncology, 2023-10, Vol.34, p.S654-S654

2023

Volltextzugriff (PDF)

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Clinical cancer research, 2019-04, Vol.25 (8), p.2442-2449

2019

Volltextzugriff (PDF)

Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib

JAMA dermatology (Chicago, Ill.), 2015-01, Vol.151 (1), p.102

2015

Volltextzugriff (PDF)

1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma

Annals of oncology, 2024-09, Vol.35, p.S730-S731

2024

Volltextzugriff (PDF)

844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Annals of oncology, 2022-09, Vol.33, p.S935-S936

2022

Volltextzugriff (PDF)

Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma

Scientific reports, 2021-02, Vol.11 (1), p.2809-2809, Article 2809

2021

Volltextzugriff (PDF)

3:30 PM Abstract No. 345 Safety and feasibility of immuno-cryotherapy

Journal of vascular and interventional radiology, 2018-04, Vol.29 (4), p.S148-S148

2018

Volltextzugriff (PDF)

Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study

Annals of oncology, 2019-10, Vol.30, p.v561

2019

Volltextzugriff (PDF)

1375TiP - Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study

Annals of oncology, 2019-10, Vol.30, p.v561-v561

2019

Volltextzugriff (PDF)

Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

Clinical cancer research, 2020-03, Vol.26 (5), p.1126-1134

2020

Volltextzugriff (PDF)

1 – 25 von 664

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(570)
Mit Volltextzugriff
(522)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

HSP90 as a marker of progression in melanoma

Growth factor receptor-bound protein-7 (Grb7) as a prognostic marker and therapeutic target in breast cancer

PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases

Clinical characteristics associated with Spitz nevi and Spitzoid malignant melanomas: The Yale University Spitzoid Neoplasm Repository experience, 1991 to 2008

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten(-/-) melanoma

Regulation of non-AU-rich element containing c-fms proto-oncogene expression by HuR in breast cancer

Identification of Two Forms of Human Plasma Renalase, and Their Association With All-Cause Mortality

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of BrafV600E::Pten–/– melanoma

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival

Histopathology‐guided mass spectrometry differentiates benign nevi from malignant melanoma

1582P Real-world management of immune-related adverse events in the community setting

LB1122 Myeloid targeting in combination with PD1 inhibition boosts anti-tumor immunity in melanoma

1086MO Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Pregabalin for the treatment of painful hand-foot skin reaction associated with dabrafenib

1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma

844P Efficacy and safety of lifileucel, an investigational autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma previously treated with anti-LAG3 antibody

Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma

3:30 PM Abstract No. 345 Safety and feasibility of immuno-cryotherapy

Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study

1375TiP - Pembrolizumab (pembro) plus lenvatinib (len) for first-line treatment of patients (pts) with advanced melanoma: Phase III LEAP-003 study

Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death

Suchergebnisse filtern